Business Wire

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
Nasdaq

GRI Bio, Inc. Advances Global Patent Strategy with European Patent Grant for NKT Cell Modulator Innovation

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...

GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and ...
Nasdaq

GRI Bio, Inc. CEO Marc Hertz Discusses Advancements in NKT Cell Modulators for IPF in Recent Virtual Investor Segment

GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...
GEN

Off-the-Shelf Immunotherapy Demonstrates Multipronged Attack Against Cancer

UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
Cure Today

Off-the-Shelf Immunotherapy May Offer Benefits in Kidney Cancer

AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...